Recent Innovative Formulation and Evaluation of Atorvastatin and Fusidic Acid Cream for Enhanced Diabetic Wound Healing as Novel Drug Delivery Systems

Background: Chronic diabetic wounds are challenging to treat due to combined issues of impaired tissue repair and high infection risk. Atorvastatin (a statin with pleiotropic effects) and Fusidic Acid (an antibiotic effective against skin pathogens including MRSA) each address different facets of diabetic wound pathology. In the present study that the developed a novel topical cream co-loaded with Atorvastatin (AT) and Fusidic Acid (FA) to leverage their complementary actions. Methods: The combination cream was formulated via melt-emulsification and optimized for physicochemical properties (pH, viscosity, spreadability, homogeneity). Compatibility and microbiological sterility were confirmed. Results: The optimized cream (F8) exhibited desirable properties: a skin compatible pH (5.1–6.0), low viscosity with excellent spreadability, homogeneous texture, and no microbial contamination. Conclusion: It was concluded that the best Cream Formulation F8 of the Atorvastatin and Fusidic Acid Cream NDDS was found to be optimized formulation possessed excellent evaluated parameters among the Cream Formulations NDDS. These formulations favorable properties and efficacy indicate it as a promising strategy for improving outcomes in infected diabetic wounds. Formulation scientist from his experience and knowledge have to significantly in the preformulation study stage and is an important factor in the NDDS (Novel Drug Delivery Systems) product development process.